Home › Soft Tissue Sarcoma › Wisconsin › Madison
Soft Tissue Sarcoma clinical trials in Madison, WI
3 studies for Soft Tissue Sarcoma are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RecruitingPhase 1/2
- University of Wisconsin, Madison
About Soft Tissue Sarcoma
Soft tissue sarcoma refers to cancer that begins in the muscle, fat, vessels or tendons. It can cause a lump or swelling. See which treatments are available
More about Soft Tissue Sarcoma on MedlinePlus
Soft Tissue Sarcoma trials in other cities
- Houston, TX32 studies
- New York City, NY20 studies
- Boston, MA18 studies
- St. Louis, MO14 studies
- Los Angeles, CA13 studies
- Columbus, OH13 studies
- Washington, DC12 studies
- Memphis, TN11 studies
- Philadelphia, PA10 studies
- Queens, NY9 studies
- Rochester, MN9 studies
- Aurora, CO9 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer22 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia16 studies
- Cancer (all types)15 studies
- Melanoma15 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Lung Cancer10 studies
- Pancreatic Cancer10 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.